This document discusses cancer immunotherapy and provides an overview of the market and clinical pipeline. It notes that cancer immunotherapy utilizes the body's immune system to target cancerous cells and has advantages over conventional treatments like chemotherapy. The market for cancer immunotherapy has grown significantly in recent years and is expected to continue expanding due to the development of new immunotherapies. The document also outlines the large number of immunotherapies currently in clinical trials, including monoclonal antibodies, vaccines, oncolytic viruses, cytokines, and cell therapies. It analyzes the competitive landscape and clinical pipelines of major pharmaceutical companies developing cancer immunotherapies.

1. Cancer Immunotherapy Market & Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com Page 1
Cancer immunotherapy is a multidisciplinary approach used to eradicate, cure, reduce,
morbidity and mortality caused by cancer. It is an umbrella term used for therapies that
utilizes body’s immune system to overcome progression and proliferation of cancerous cells in
the body. Flexibility of this approach allows the oncologists to target different kinds of
malignancies with high confidence rates. Conventional modalities like chemotherapy provides
modest effects but their severe side effects are main reason for the wide spread acceptance
of cancer immunotherapy. Clinical data also suggests that cancer immunotherapy has the
ability to surpass other methods to treat cancer due to superior pharmacological efficiency.
With changing time cancerous cells also undergo changes due to which artificially developed
molecule may become unavailable after some time in imparting pharmacological effect.
Cancer immunotherapies are known to provide long-term pharmacological effect against
cancer and prevent relapse in majority of cases. These effects may be provided by different
class of therapeutics but increased life span is a major issue for cancer patients due to which
they are opting for cancer immunotherapies. Development in this field has been used to
target various malignancies especially those which have higher incidence rates like breast
cancer, skin cancer, prostate, lung cancer and others. While lesser know like urinary bladder
cancer are also witnessing introduction of cancer immunotherapeutics.
Theoretical concept of cancer immunotherapy has been materialized and passed through
various stages of industry life cycle. Competition is severe in this segment due to mature
market and large number of drug candidates for same disease indication. Many
pharmaceutical companies are actively engaged in the development of cancer
immunotherapies to provide better health care to patients. Entirely new approach to
eliminate cancer has been taken to remain competitive which is giving rise to market
introduction of innovative products. As a result, pharmaceutical companies are expected to
generate more revenues by providing better cancer immuno therapies to patients.
After clinical success, commercial success is a major challenge in front of these
pharmaceutical companies. Some populations are more prone to a particular type of
malignancy while other are susceptible or regulatory framework of one territory may or may
not have amenability, these are some of the major factors responsible for commercial success
which should be notices while designing marketing strategy. Many pharmaceutical companies
have successfully commercialized their cancer immunotherapies across the globe despite

2. Cancer Immunotherapy Market & Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com Page 2
various issues. As a result, pharmaceutical companies across the globe are competing to
occupy major shares in global market. In this regard, pharmaceutical companies from the
European Union, North Americas and Asian region are trying to improve their capabilities.
Several small sized to large sized pharmaceutical companies could be observed in cancer
immunotherapy segment responsible for increase in global market size. Every year new
pharmaceutical firm is entering in this market segment responsible for advancement of this
segment. They are being used as first line treatments for curing cancer while so of them are
used for combinatorial therapy. Clinical pipeline of cancer immunotherapeutic is growing
strong and various products are at different stages of clinical trials which are expected to
enter in market in coming years.
Many new pharmaceutical are also entering in the cancer immunotherapy like Juno
Therapeutics whose roots could be traced back to 2013 reflecting the interest of
entrepreneurs in this segment. While already existing huge pharmaceutical companies with
highly developed cancer immunotherapy pipeline like Merck, Roche, GSK, Novartis and Teva
pharmaceuticals are giving emphasis on improving the already existing molecule. This will
offer more cost arbitrage and pre existing marketing channels will help in occupying the
market shares. For instance, Genetech patent for Herceptin in 1998 for metastatic breast
cancer and presently they are improving its drug design to provide better safety and efficacy
profiles.
Different pharmaceutical companies are introducing immunotherapy that could be used for
multiple drug indication which is going to increase competition in near future. This feature
enables the oncologists to treat patient with multiple symptoms with same methodology but
at market side it creates unclear boundaries. It is good for patients in this way they would be
at lower risk of developing other types of malignancies. Pharmaceutical companies also get
benefit from this but having more market penetration. As a result, flexible and versatile
cancer immunotherapies are in higher demand as compared to presently available cancer
therapeutics which have limited coverage.
Research and development could be considered as a backbone of cancer immunotherapies
which is required to maintain dominance in market by introducing superior products.
Pharmaceutical companies are diverging more funds towards this segment to generate huge
revenues in coming years. Another benefit of investing in research and development seems to

3. Cancer Immunotherapy Market & Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com Page 3
be the continuous supply of innovative products so that the upcoming products are always in
the clinical pipeline. Consequently, Monoclonal antibodies, cell based therapies and cytokine
therapies were developed as a part of cancer immunotherapy to maintain diversification and
continuous supply of products in market. This market segment has high growth potential
owing to rapid development and huge unmet medical necessities.
Pharmaceutical market is witnessing steady increase of cancer immunotherapy products in
past decade. Monoclonal antibodies, cell based therapies and cytokine therapies are major
contenders in cancer therapeutics market. Cytokines were earliest products to enter in this
market segment but their modest efficacy and higher costs limited their market penetration.
Presently, they are used in combinatorial approach with monoclonal antibodies and cell based
therapies. This trend could be observed in case of breast cancer where large numbers of
monoclonal antibody based cancer immunotherapeutic drugs are available in market. On the
other hand, cell based immunotherapeutic have single product called Provenge developed by
Dendreon Corporation to prevent prostate cancer.
Market introduction of novel therapeutics with increasing pharmacological effects along with
minimized side effects at steady rates is much required. Flexibility and versatility of cancer
immunotherapeutics seems to remain their major positive point for opting them as a part of
regular therapeutic regime. Market penetration also seems to increase several fold because of
their proven track record and wide acceptance levels among oncologists and patients. With
all these development taking place in the field of cancer immunotherapeutic its future seems
to be optimistic.
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
 Cancer Immunotherapy Market Overview
 Cancer Immunotherapy Market Dynamics
 Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
 Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
 Cancer Vaccine Clinical Pipeline by Phase & Country
 Oncolytic Viruses Clinical Pipeline by Phase & Country
 Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
 Cancer Cell Therapy Clinical Trial Insight by Phase & Country

4. Cancer Immunotherapy Market & Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com Page 4
 Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40
Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical
Pipeline
Table of Contents
1. Introduction to Cancer Immunotherapy (Page 6)
2. Mechanism of Cancer Immunotherapy (Page 11)
2.1 Genetic engineering
2.2 Hybridoma Technology
2.3 Humanization of Monoclonal Antibodies
2.4 Overcoming the HAMA Response via Modern Technology
3. Types of Cancer Immunotherapy (Page 14)
3.1 Monoclonal Antibodies
3.2 Checkpoint Inhibitors
3.3 Vaccination
3.4 Non Specific Immunotherapies
4. Why Need for Cancer Immunotherapy (Page 23)
5. Global Cancer Immunotherapy Market Overview (Page 26)
6. Cancer Immunotherapy Market Dynamics (Page 33)
6.1 Favorable Market Drivers
6.2 Key issues to be Discussed
6.3 Future of Cancer Immunotherapy
7. Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country (Page 41)
7.1 Clinical Pipeline Overview
7.2 Clinical Pipeline Insight: Research till Registration
7.3 Marketed Cancer Monoclonal Antibodies

5. Cancer Immunotherapy Market & Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com Page 5
8. Cancer Vaccine Clinical Pipeline by Phase & Country (Page 1088)
8.1 Clinical Pipeline Overview
8.2 Clinical Pipeline Insight: Research till Registration
8.3 Marketed Cancer Vaccines
9. Oncolytic Viruses Clinical Pipeline by Phase & Country (Page 1640)
9.1 Clinical Pipeline Overview
9.2 Clinical Pipeline insight: Research till Registration
10. Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country (Page 1714)
10.1 Clinical Pipeline Overview
10.2 Clinical Pipeline Insight: Research till Preregistration
10.3 Marketed Cancer Cytokines Threapy
11. Cancer Cell Therapy Clinical Trial Insight by Phase & Country (Page 1844)
11.1 Clinical Pipeline Overview
11.2 Clinical Pipeline Insight: Research till Preregistration
11.3 Marketed Cancer Cell Therapy
12. Competitive Landscape: Business Overview & Product Pipeline (Page 1977)
12.1 Advaxis
12.2 Celldex Therapeutics
12.3 Dendreon Corporation
12.4 Galena Biopharma
12.5 ImmunoCellular Therapeutics
12.6 ImmunoGen
12.7 Inovio Pharmaceuticals
12.8 Merck
12.9 NeoStem Oncology
12.10 NewLink Genetics
12.11 Northwest Biotherapeutics
12.12 Novartis
12.13 Peregrine Pharmaceuticals

6. Cancer Immunotherapy Market & Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com Page 6
12.14 Roche
12.15 Seattle Genetics
List of Figures
Figure 1-1: Introduction to Cancer Therapies
Figure 1-2: Key Events in the History of Cancer Immunotherapy
Figure 2-1: Mechanism of Cancer Immunotherapy
Figure 3-1: Type of Cancer Immunotherapy
Figure 5-1: Cancer Immunotherapy Market Category
Figure 5-2: Cancer Immunotherapy Market (US$ Billion), 2014-2020
Figure 5-3: Cancer Immunotherapy Market by Region (%), 2014 & 2020
Figure 5-4: Regulatory Milestones for Cancer Immunotherapy
Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2014
Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2014
Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase (%), 2014
Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase (Number), 2014
Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase (%), 2014
Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase (Number), 2014
Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: Celldex Therapeutics Clinical Pipeline
Figure 12-3: Galena Biopharma Clinical Pipeline

7. Cancer Immunotherapy Market & Clinical Pipeline Insight
For Report Sample Contact: neeraj@kuickresearch.com Page 7
Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 12-5: ImmunoGen Clinical Pipeline
Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-7: NewLink Genetics Corporation Clinical Pipeline
Figure 12-8: Northwest Biotherapeutics Clinical Pipeline
Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 12-10: Seattle Genetics Clinical Pipeline